Skip to main content

Dupilumab Efficacious for Atopic Dermatitis in Young Children

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 11, 2024.

via HealthDay

WEDNESDAY, Dec. 11, 2024 -- Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study published in the December issue of Advances in Therapy.

Mark Boguniewicz, M.D., from University of Colorado School of Medicine in Aurora, and colleagues evaluated the impact of type 2 comorbidities on the response to and safety of dupilumab in young children with AD. The analysis included children (aged 6 months to 5 years) with moderate-to-severe AD.

The researchers found that at week 16, significantly more patients receiving dupilumab versus placebo, with or without asthma and allergic rhinitis (AR), achieved an Investigator’s Global Assessment (IGA) score of 0/1 and a ≥75 percent improvement in the Eczema Area and Severity Index. Significantly more patients receiving dupilumab with food allergies (FAs) and numerically more patients without FAs achieved an IGA score of 0/1 versus placebo. Compared with those taking placebo, numerically more patients receiving dupilumab with asthma and significantly more patients without asthma achieved a ≥4-point reduction in the weekly average of the daily score on the Worst Scratch/Itch Numeric Rating Scale (WSI-NRS). Similarly, a ≥4-point reduction in the weekly average of the daily score on the WSI-NRS was achieved by significantly more patients receiving dupilumab than placebo with or without AR and with or without FAs. Safety was consistent with the known dupilumab safety profile.

"These results suggest that dupilumab treatment may be effective in children with or without other type 2 conditions," the authors write.

The study was funded by Sanofi and Regeneron, which manufacture dupilumab.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Suicidal Ideation Risk Elevated for Patients With Atopic Eczema

WEDNESDAY, Sept. 17, 2025 -- Patients with atopic eczema (AE) have an increased risk for suicidal ideation (SI), according to a study presented at the European Academy of...

Lebrikizumab Efficacious, Safe for Patients With Skin of Color, Eczema

WEDNESDAY, Aug. 13, 2025 -- For patients with skin of color and atopic dermatitis (AD), lebrikizumab is efficacious and safe, according to a study published online July 15 in the...

Novel Treatments Recommended for Management of Atopic Dermatitis in Adults

FRIDAY, July 25, 2025 -- In an update to the guidelines for managing atopic dermatitis in adults, four new treatment recommendations are presented. The focused update was...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.